Navigation Links
Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer
Date:6/25/2008

BEDFORD, Mass., June 25 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX) today announced that the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), on June 24, 2008, in connection with Hologic's previously announced tender offer for all of the outstanding shares of the common stock of Third Wave Technologies, Inc. (Nasdaq: TWTI). The early termination of the waiting period under the HSR Act satisfies the conditions to the tender offer related to the expiration or termination of any applicable waiting periods under the HSR Act and other state and foreign regulatory laws relating to the restraint of trade or lessening of competition. The tender offer remains subject to certain other conditions described in the Offer to Purchase.

As previously announced, Hologic commenced a Tender Offer on June 18, 2008 for all of the outstanding shares of Third Wave common stock for $11.25 per share in cash. The tender offer is scheduled to expire at 12:00 midnight, New York City time, on July 16, 2008.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity imaging. For more information visit http://www.hologic.com.

Additional Information

This description contained herein is neither an offer to purchase nor a solicitation of an offer to sell shares of Third Wave. The tender offer is being made pursuant to a Tender Offer Statement and related materials. Third Wave shareholders are advised to read the Tender Offer Statement and related materials filed by Hologic with the U.S. Securities and Exchange Commission (the "SEC"). At the time the tender offer commenced, Hologic and Thunder Tech Corp. (a wholly- owned subsidiary of Hologic) filed a Tender Offer Statement on Schedule TO containing an Offer to Purchase, the form of the letter of transmittal and other documents relating to the tender offer, and Third Wave filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. These documents contain important information about the tender offer, including the terms and conditions of the tender offer, and shareholders of Third Wave are urged to read them carefully. Shareholders of Third Wave are able to obtain a free copy of these documents at http://www.hologic.com and the website maintained by the SEC at http://www.sec.gov. In addition, shareholders are able to obtain a free copy of these documents by contacting Hologic or Third Wave.

Contact:

Glenn P. Muir

Executive Vice President & CFO

Hologic, Inc.

(781) 999-7300

Frances Doria

Director, Investor Relations

Hologic, Inc.

(781) 999-7377


'/>"/>
SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hologic, Inc. to Host Investor Reception at the RSNA Trade Show
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... planning services and products in the developing world, is pleased to release their ... prevent over 5 million unwanted pregnancies, almost 14,000 maternal deaths and 3.8 million ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Clearinghouse supporting the real time adjudication of medical service claims by Pharmacy Benefit ... their current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard ...
(Date:5/25/2016)... ... , ... The University of San Francisco (USF) has named Margaret Wooding Baker ... of more than 100 full-time faculty and staff, and serve as a member of ... , Baker comes to USF from the University of Washington in Seattle, where she ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & Wellness Center ... hands of time of female aging. The Juliet™ procedure helps to ... such as leakage, laxity, itchiness and pain have reported real relief from these and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State ... Meeting for their work on visual evoked potential and human attention. The article, ... used the Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... N.J. , May 24, 2016 ... oncology drug development company, today provided an update ... dose escalating clinical trial combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  GEN-1 is an IL-12 DNA ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
Breaking Medicine Technology: